2 completed, 2 terminated, 1 unknown. 5 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Completed 2, Terminated 2, Unknown 1 |
| Phase 2 | 1 | Completed 1 |
Follow camostat: new trials by email Literature Review of camostat trials Research Report on camostat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The DAWN Antivirals Trial for Ambulatory COVID-19 Patients Camostat, Placebo, Molnupiravir - Covid19, SARS-CoV Infection | Phase 3 | Terminated | KU Leuven | 44 | 2021-06-15 | 2022-10-03 |
| CAMOVID : Evaluation of Efficacy and Safety of Camostat Mesylate for the Treatment of SARS-CoV-2 Infection - COVID-19 in Ambulatory Adult Patients Camostat Mesylate, Placebo - Covid19 | Phase 3 | Terminated | Assistance Publique - Hôpitaux de Paris | 70 | 2020-12-03 | 2022-02-10 |
| A Study of FOY-305 in Patients With SARS-Cov-2 Infection (COVID-19) FOY-305, Placebo - SARS-CoV-2 Infection (COVID-19) | Phase 3 | Completed | Ono Pharmaceutical Co., Ltd. | 155 | 2020-11-09 | 2024-04-05 |
| ACTIV-2: A Study for Outpatients With COVID-19 bamlanivimab 7000mg, BRII-196+BRII-198, AZD7442 (IV) - Coronavirus, Covid19 | Phase 2 / Phase 3 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 4044 | 2020-08-19 | 2024-08-02 |
| Open Label Study to Compare Efficacy, Safety and Tolerability of Hydroxychloroquine Combined With Azithromycin Compared to Hydroxychloroquine Combined With Camostat Mesylate and to "no Treatment" in SARS CoV 2 Virus hydroxychloroquine in combination with camostat mesylate, Hydroxychloroquine in combination of Azithromycin - COVID - 19 | Phase 3 | Unknown | Sheba Medical Center | 250 | 2020-04-11 | 2020-04-21 |
COVID-19 (5) · Severe Acute Respiratory Syndrome (2) · Coronaviridae Infections (1) · Coronavirus Infections (1) · Nidovirales Infections (1) · RNA Virus Infections (1) · Virus Diseases (1)
Assistance Publique - Hôpitaux de Paris (1) · KU Leuven (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Ono Pharmaceutical Co., Ltd. (1) · Sheba Medical Center (1)
Argentina (1) · Belgium (1) · Brazil (1) · Canada (1) · France (1) · Guatemala (1) · Israel (1) · Japan (1) · Mexico (1) · Philippines (1) · Puerto Rico (1) · South Africa (1) · United States (1)
David Smith, MD, MAS (1) · Naoyuki Komura (1)
PMID 34473343, PMID 34981077, PMID 35713300, PMID 35793677, PMID 35797235, PMID 35995785, PMID 36163020, PMID 36210483, PMID 36289399, PMID 36301549, PMID 36378539, PMID 36467293, PMID 36661240, PMID 36802755, PMID 37068272, PMID 37099295, PMID 37279602, PMID 37650230, PMID 37650232, PMID 37650233, PMID 37650236, PMID 37855026, PMID 39018444, PMID 39028902, PMID 41823222, PMID 42148571